Precipio
Pairs hematologic-cancer pathology testing with proprietary diagnostic products.
Something off on this page? Send us feedback.
Profile
Offers specialized cancer diagnostic testing through its pathology laboratory and sells HemeScreen and IV-Cell diagnostic products. The lab and product divisions work together, with laboratory services functioning as a self-funded R&D unit.
Combines a clinical hematologic-cancer pathology laboratory with proprietary diagnostic-product development. The pathology-services division supplies specialized cancer diagnostic testing to physicians, hospitals, and laboratories, principally for hematologic cancers.
Its product division markets HemeScreen and IV-Cell. HemeScreen has expanded from a myeloproliferative-neoplasms panel into panels for acute myeloid leukemia, chronic lymphocytic leukemia, cytopenia, and BCR-ABL; the company also released BCR-ABL1 and Bloodhound MPN assays with complementary analysis software.
Laboratory services are integrated with product development and function as a self-funded R&D unit. The pathology-services business depends on testing volumes and reimbursement levels.
Company facts
Categories
Key statistics
Year to date +20.6% · Average volume (30d) 127.0K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026Q2 FY26 | −$2.00 | −$0.12 | +94.0% | $1.7M | $7.0M | +319.2% | +1.70% |
| Mar 30, 2026Q4 FY25 | — | −$0.81 | — | — | $8.0M | — | +4.60% |
| Nov 14, 2025Q3 FY25 | — | −$0.05 | — | — | $6.2M | — | +8.79% |
| Aug 13, 2025Q2 FY25 | — | $0.05 | — | — | $5.7M | — | +2.94% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $4.3M | $5.7M | $6.2M | $8.0M | $6.3M | $7.0M | |
| Gross profit | $2.1M | $2.4M | $3.0M | $3.1M | $2.7M | $3.1M | |
| Operating income | −$859.0K | −$824.0K | −$61.0K | $542.0K | −$1.4M | −$599.0K | |
| Net income | −$884.0K | $74.0K | −$79.0K | $526.0K | −$1.4M | −$219.0K | |
| Diluted EPS | −$0.59 | $0.05 | −$0.05 | $0.33 | −$0.81 | −$0.12 | |
| Gross margin | 50.3% | 43.0% | 48.8% | 39.3% | 43.2% | 44.7% | |
| Operating margin | -20.2% | -14.6% | -1.0% | 6.8% | -22.7% | -8.5% |
Fiscal years (4-quarter sums)FY21 $8.8M · FY22 $9.4M · FY23 $14.4M · FY24 $18.5M · FY25 $24.0M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $3.1M · Total debt $3.3M · Total assets $21.3M · Shareholders' equity $14.8M
Dividends
No dividends on record.
Ownership
Shares outstanding 1.78M · Float 1.40M · 78.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Leviticus Partners LP | 158.6K | 9.10% | 13G | Feb 10, 2026 |
| David Seth Cohen · director | 55.2K | 3.09% | Form 4 | Jul 16, 2026 |
| BlackRock, Inc. | 29.0K | 1.63% | 13F | May 13, 2026 |
| Vanguard Capital Management LLC | 25.5K | 1.43% | 13F | May 15, 2026 |
| Topline Capital Management, LLC | 24.6K | 1.38% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 21, 2026 | Richard A. Sandberg | director | −900 | $25.02 |
| May 20, 2026 | Richard A. Sandberg | director | −2,534 | $24.91 |
| May 19, 2026 | Richard A. Sandberg | director | −600 | $24.42 |
| Apr 1, 2026 | Ahmed Zaki Sabet | officer: Chief Operating Officer | +19 | $27.93 |
| Jul 8, 2025 | Ahmed Zaki Sabet | officer: Chief Operating Officer | +31 | $16.30 |
Peers
- NeoGenomics
Cancer-focused oncology diagnostics and pathology laboratory network
- Labcorp
National laboratory services provider with oncology diagnostics
- Quest Diagnostics
National diagnostic-services provider with oncology and molecular testing
- Fulgent Genetics
Specialty pathology and hematopathology testing through Inform Diagnostics
- Guardant Health
Liquid-biopsy oncology testing for therapy selection and monitoring
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Precipio | $28.85 | +0.45% | $51.5M | — | — | 1.9 | +24.2% |
| NeoGenomics | $18.20 | +0.86% | $463.8M | — | 64.9 | 0.6 | +11.2% |
| Labcorp | $333.00 | −0.68% | $27.48B | 27.7 | 17.7 | 1.9 | +5.8% |
| Quest Diagnostics | $244.50 | +0.69% | $26.79B | 25.8 | 21.2 | 2.3 | +10.2% |
| Fulgent Genetics | $19.61 | −0.05% | $556.9M | — | — | 1.7 | +4.4% |
| Guardant Health | $161.50 | −0.03% | $21.67B | — | — | 18.3 | +44.3% |
| Median | 26.7 | 21.2 | 1.9 | +10.2% |